Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection

Journal of Clinical Investigation

Volumn 124, Issue 3, 2014, Pages 1255-1267

  Kong, Qiongman ^a   Chang, Ling Chu ^a   Takahashi, Kou ^a   Liu, Qibing ^a   Schulte, Delanie A ^a   Lai, Liching ^a   Ibabao, Brian ^a   Lin, Yuchen ^a   Stouffer, Nathan ^a   Mukhopadhyay, Chitra Das ^a   Xing, Xuechao ^b   Seyb, Kathleen I ^b   Cuny, Gregory D ^b,c   Glicksman, Marcie A ^b   Lin, Chien Liang Glenn ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; EXCITATORY AMINO ACID TRANSPORTER 2; NEUROPROTECTIVE AGENT; OSU 0212320; PROTEIN KINASE C; PYRIDAZINE DERIVATIVE; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; EXCITOTOXICITY; FEMALE; LIFE EXTENSION; MALE; MORTALITY; MOTOR PERFORMANCE; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SEIZURE; TEMPORAL LOBE EPILEPSY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTERIOR HORN CELLS; ASTROCYTES; CELL LINE; COCULTURE TECHNIQUES; ENZYME ACTIVATION; EXCITATORY AMINO ACID TRANSPORTER 2; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION, MISSENSE; NEUROPROTECTIVE AGENTS; PILOCARPINE; PROTEIN BIOSYNTHESIS; PROTEIN KINASE C; PYRIDAZINES; PYRIDINES; RATS; STATUS EPILEPTICUS; SUPEROXIDE DISMUTASE; TISSUE DISTRIBUTION; TRANSCRIPTION FACTORS;

EID: 84896791747     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66163     Document Type: Article

References (54)

1. Choi DW. Ionic dependence of glutamate neurotoxicity. J Neurosci. 1987;7(2):369-379.
2. Chaudhry FA, Lehre KP, van Lookeren Campagne M, Ottersen OP, Danbolt NC, Storm-Mathisen J. Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry. Neuron. 1995;15(3):711-720.
3. Rothstein JD, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16(3):675-686.
4. Lin CG, Kong Q, Cuny GD, Glicksman MA. Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases. Future Med Chem. 2012;4(13):1689-1700.
5. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995;38(1):73-84.
6. Li S, Mallory M, Alford M, Tanaka S, Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol. 1997; 56(8):901-911.
7. Jacob CP, et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis. 2007; 11(1):97-116.
8. Acharya MM, Hattiangady B, Shetty AK. Progress in neuroprotective strategies for preventing epilepsy. Prog Neurobiol. 2008;84(4):363-404.
9. Yi JH, Hazell AS. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int. 2006;48(5):394-403.
10. Hazell AS. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem Int. 2007;50(7-8):941-953.
11. Zelenaia O, et al. Epidermal growth factor receptor agonists increase expression of glutamate transporter GLT-1 in astrocytes through pathways dependent on phosphatidylinositol 3-kinase and transcription factor NF-kappaB. Mol Pharmacol. 2000;57(4):667-678.
12. Figiel M, Maucher T, Rozyczka J, Bayatti N, Engele J. Regulation of glial glutamate transporter expression by growth factors. Exp Neurol. 2003; 183(1):124-135.
13. Lee SG, Su ZZ, Emdad L, et al. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem. 2008; 283(19):13116-13123.
14. Tian G, et al. Translational control of glial glutamate transporter EAAT2 expression. J Biol Chem. 2007; 282(3):1727-1737.
15. Rothstein JD, et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433(7021):73-77.
16. Colton CK, et al. Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity. J Biomol Screen. 2010;15(6):653-662.
17. Bristol LA, Rothstein JD. Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann Neurol. 1996;39(5):676-679.
18. Xing X, et al. Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. Bioorg Med Chem Lett. 2011; 21(19):5774-5777.
19. Guo H, et al. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet. 2003;12(19):2519-2532.
20. Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264(5166):1772-1775.
21. Chiu AY, et al. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci. 1995; 6(4):349-362.
22. Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci. 1997;152(suppl 1):S67-S73.
23. During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet. 1993; 341(8861):1607-1610.
24. Cavus I, et al. Extracellular metabolites in the cortex and hippocampus of epileptic patients. Ann Neurol. 2005;57(2):226-235.
25. Tian GF, et al. An astrocytic basis of epilepsy. Nat Med. 2005;11(9):973-981.
26. Binder DK, Steinhauser C. Functional changes in astroglial cells in epilepsy. Glia. 2006;54(5):358-368.
27. Wetherington J, Serrano G, Dingledine R. Astrocytes in the epileptic brain. Neuron. 2008;58(2):168-178.
28. Benarroch EE. Astrocyte-neuron interactions: implications for epilepsy. Neurology. 2009; 73(16):1323-1327.
29. Kong Q, Takahashi K, Schulte D, Stouffer N, Lin Y, Lin CL. Increased glial glutamate transporter EAAT2 expression reduces epileptogenic processes following pilocarpine-induced status epilepticus. Neurobiol Dis. 2012;47(2):145-154.
30. Evdokimova V, Ovchinnikov LP, Sorensen PH. Y-box binding protein 1: providing a new angle on translational regulation. Cell Cycle. 2006; 5(11):1143-1147.
31. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003;25(7):691-698.
32. Tanaka T, Ohashi S, Funakoshi T, Kobayashi S. YB-1 binds to GluR2 mRNA and CaM1 mRNA in the brain and regulates their translational levels in an activity-dependent manner. Cell Mol Neurobiol. 2010;30(7):1089-1100.
33. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000; 351(pt 1):95-105.
34. Keranen LM, Dutil EM, Newton AC. Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. Curr Biol. 1995;5(12):1394-1403.
35. van Marum RJ. Update on the use of memantine in Alzheimer's disease. Neuropsychiatr Dis Treat. 2009; 5:237-247.
36. Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17(18):1942-1199.
37. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012; 3:CD001447.
38. Northeast Amyotrophic Lateral Sclerosis Consortium. Statement on the Clinical Trial of Cetriaxone. Clinical ALS Trials information Web site. http://www.nealsconsortium.org/news-ceftriaxone-announcement.php. Updated August 8, 2012. Accessed July 14, 2013.
39. Melzer N, et al. A B-Lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS One. 2008; 3(9):e3149.
40. Carbone M, Duty S, Rattray M. Riluzole elevates GLT-1 activity and levels in striatal astrocytes. Neurochem Int. 2012;60(1):31-38.
41. Scott S, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008;9(1):4-15.
42. Kong Q, Carothers S, Chang Y, Lin CG. The importance of preclinical trial timing - a potential reason for the disconnect between mouse studies and human clinical trials in ALS. CNS Neurosci Ther. 2012;18(9):791-793.
43. Ludolph AC, et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler. 2007; 8(4):217-223.
44. Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology. 1998;50(1):62-66.
45. Notenboom RG, et al. Up-regulation of hippocampal metabotropic glutamate receptor 5 in temporal lobe epilepsy patients. Brain. 2006; 129(pt 1):96-107.
46. Liu HT, Tashmukhamedov BA, Inoue H, Okada Y, Sabirov RZ. Roles of two types of anion channels in glutamate release from mouse astrocytes under ischemic or osmotic stress. Glia. 2006;54(5):343-357.
47. Domercq M, Brambilla L, Pilati E, Marchaland J, Volterra A, Bezzi P. P2Y1 receptor-evoked glutamate exocytosis from astrocytes: control by tumor necrosis factor-alpha and prostaglandins. J Biol Chem. 2006;281(41):30684-30696.
48. Shan X, Chang Y, Lin CL. Messenger RNA oxidation is an early event preceding cell death and causes reduced protein expression. FASEB J. 2007; 21(11):2753-2764.
49. Butchbach ME, Tian G, Guo H, Lin CL. Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function. J Biol Chem. 2004;279(33):34388-34396.
50. Tian G, Kong Q, Lai L, Ray-Chaudhury A, Lin CL. Increased expression of cholesterol 24S-hydroxylase results in disruption of glial glutamate transporter EAAT2 association with lipid rafts: a potential role in Alzheimer's disease. J Neurochem. 2010; 113(4):978-989.
51. Chang Y, et al. Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS. PLoS One. 2008; 3(8):e2849.
52. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol. 1972;32(3):281-294.
53. Shapiro LA, Figueroa-Aragon S, Ribak CE. Newly generated granule cells show rapid neuroplastic changes in the adult rat dentate gyrus during the first five days following pilocarpine-induced seizures. Eur J Neurosci. 2007;26(3):583-592.
54. Pitsch J, Schoch S, Gueler N, Flor PJ, van der Putten H, Becker AJ. Functional role of mGluR1 and mGluR4 in pilocarpine-induced temporal lobe epilepsy. Neurobiol Dis. 2007;26(3):623-633.